"Closing The Gap: Expert Analysis Of New & Emerging Therapies Targeting LDL-C To Reduce Cardiovascular Risk"

This unique educational format on therapies which target LDL-C to reduce cardiovascular risk has been designed with you in mind; it features six modules from which you can pick and choose your curriculum based on your interests. Click to begin customizing your learning experience while proceeding at your own pace and accruing as many credits as you wish.
Only have a little time now? Register, start the first module, and continue at your convenience.

Target Audience
This activity has been designed to meet the educational needs of primary care physicians, lipidologists, endocrinologists, cardiologists and high-level allied health professionals involved in the management of patients who would benefit from treatment of elevated low-density lipoprotein cholesterol (LDL-C) to reduce coronary heart disease (CHD) risk.

Statement of Need/Program Overview
Dyslipidemia is a major risk factor for CHD, which remains the leading cause of death and disability in both men and women in the United States. Elevated LDL-C, low high-density lipoprotein cholesterol (HDL-C), and hypertriglyceridemia are among the disorders that encompass dyslipidemia. Although mean total cholesterol (TC) and LDL-C levels have declined over the past decade due to the use of lipid-lowering drugs, abnormal lipid levels remain a significant problem among patients with and without existing heart disease. In fact, recent estimates from the American Heart Association indicate that more than 98 million US adults still have elevated TC (≥200 mg/dL), more than 71 million have elevated LDL-C (≥130 mg/dL), and over 48 million have low HDL-C (<40 mg/dL).

While the prevalence of dyslipidemia remains high, screening, awareness, and treatment efforts continue to be suboptimal. According to data from the National Health and Nutrition Examination Survey (NHANES), among patients with elevated LDL-C, more than one-third had not been previously screened for dyslipidemia, approximately a quarter were screened but not told they had elevated LDL-C, and nearly 40% were not treated adequately. More recent data from NHANES showed that although the prevalence of dyslipidemia was 25% among individuals with no cardiovascular disease (CVD), only 63% of those were aware of their dyslipidemia and 38% were treated. Among patients with CVD, prevalence of dyslipidemia was 35%, but among these, only 83% were aware of their dyslipidemia and 76% treated.

For information about the accreditation of this program, please contact Medical Education Resources at (800) 421-3756.

Physician Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and Educational Concepts in Medicine (ECM). MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Medical Education Resources designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy Credit
Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy (2.75 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Program Number - 0816-9999-15-054-H01-P)

Pharmacists should complete the entire activity in order to receive 2.75 contact hours.

This activity is certified as knowledge based CPE.

Nursing Credit
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This CE activity provides 2.75 contact hours of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 2.75 contact hours.

Presenting Faculty
Christie M. Ballantyne, MD, FACP, FACC
Professor of Medicine
Chief, Section of Cardiovascular Research
Chief, Section of Cardiology
Department of Medicine
Baylor College of Medicine
Director, Center for Cardiovascular Disease Prevention
Methodist DeBakey Heart & Vascular Center
Houston, Texas

Daniel J. Rader, MD
Seymour Gray Professor of Molecular Medicine
Chair, Department of Genetics
Chief, Division of Translational Medicine and Human Genetics, Department of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Henry N. Ginsberg, MD
Irving Professor of Medicine
Director, Irving Institute for Clinical and Translational Research
Columbia University Medical Center
New York, New York

Roger S. Blumenthal, MD
Kenneth Jay Pollin Professor of Cardiology
Director, Johns Hopkins Ciccarone Center for the Prevention of Heart Disease
Johns Hopkins School of Medicine
Baltimore, Maryland

Educational Objectives
After completing this activity, the participant should be better able to:
  • Summarize the current status of screening, awareness, and treatment of individuals with dyslipidemia
  • Assess the challenges of achieving LDL-C treatment goals with existing statin therapies and strategies to overcome these challenges
  • Engage patients in a discussion on key guideline updates for the management of dyslipidemia/elevated LDL-C, including challenges and controversies surrounding their implementation
  • Describe the rationale for the use of PCSK9 inhibitors to lower LDL-C in patients with dyslipidemia
  • Identify the roles, benefits, and risks of PCSK9 inhibitors, MTP inhibitors, and Apo B inhibitors for LDL-C lowering in patients with dyslipidemia
  • Provide appropriate care and counsel for patients and their families
Disclosure of Conflicts of Interest
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Name of Faculty Presenter and Planning Committee Reported Financial Relationship
Christie Ballantyne, MD, FACP, FACC Grants/Research Support: Abbott Diagnostic, Amarin, Amgen, Eli Lilly, Esperion, Novartis, Pfizer, Otsuka, Regeneron, Roche Diagnostic, Sanofi-Synthelabo, Takeda, NIH, AHA, ADA.
Consulting Fees: Abbott Diagnostics, Amarin, Amgen, AstraZeneca, Eli Lilly, Esperion, Genzyme, Matinas BioPharma, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi-Synthelabo
Roger Blumenthal, MD No financial relationships to disclose.
Daniel J. Rader, MD Consulting Fees: Aegerion, Eli Lilly, Sanofi.
Royalty/Patent Holder: Patent on lomitapide licensed to Aegerion.
Henry N. Ginsberg, MD Grants/Research Support: Amgen, Merck, Sanofi-Regeneron.
Consulting Fees: Amgen, Astra-Zeneca, BMS, Kowa, Merck, Sanofi.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Planner or Manager Reported Financial Relationship
MER Content Managers No financial relationships to disclose.
ECM: Patrick J. Crowley, MBA, President/CEO; Dina Kouveliotes, Account Manager; Deb Hughes, Medical Writer; Jodi Andrews, VP, Operations No financial relationships to disclose.


Method of Participation
There are no fees for participating in and receiving credit for this activity. During the period July 22, 2015 through July 22, 2016, participants must:
  • Read the learning objectives and faculty disclosures
  • Study the educational activity
  • Complete the posttest by recording the best answer to each question in the answer key on the evaluation form
  • Complete the evaluation form
A statement of credit will be available only upon completion of the activity evaluation form and a completed posttest with a score of 70% or better.

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Educational Concepts in Medicine, and/or Sanofi. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Medical Education Resources, Educational Concepts in Medicine, and/or Sanofi. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Commercial Support
This activity is supported by an educational grant from:
Sanofi US and Regeneron Pharmaceuticals, Inc


Release Date: July 22, 2015
Expiration Date: July 22, 2016
Estimated Time to Complete Activity:
This activity consists of 6 short learning modules and is accredited for up to 2 hours and 45 minutes. Activity time is based on number of modules completed. Save your progress and return to complete additional modules at your convenience.
Minimum System Requirements:

  • Internet Explorer 7 (or higher) or
  • Mozilla Firefox 4 (or higher)
  • Google Chrome (latest version)
  • Safari for MAC (latest version)
  • Adobe Acrobat 6.0 (or higher)
  • Screen resolution 1024 x 768

Click here to contact Medical Education Resources

This activity is supported by an educational grant from: Sanofi US and Regeneron Pharmaceuticals, Inc
This activity is jointly provided by:
All Rights Reserved. Use of this website is governed by the Terms of Use | Privacy Policy
© 2015 Cardiovascular & Metabolic Health Foundation. All rights reserved.